4laz
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | ''' | + | ==Crystal structure of human AR complexed with NADP+ and {5-chloro-2-[(4-iodobenzyl)carbamoyl]phenoxy}acetic acid== |
+ | <StructureSection load='4laz' size='340' side='right' caption='[[4laz]], [[Resolution|resolution]] 0.85Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | [[4laz]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LAZ OCA]. <br> | ||
+ | <b>Related:</b> [[1us0|1us0]], [[2iki|2iki]], [[4lau|4lau]], [[4lb3|4lb3]], [[4lb4|4lb4]], [[4lbr|4lbr]], [[4lbs|4lbs]]<br> | ||
+ | <b>Activity:</b> <span class='plainlinks'>[http://en.wikipedia.org/wiki/Glucokinase Glucokinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.1.2 2.7.1.2] </span><br> | ||
+ | == Publication Abstract from PubMed == | ||
+ | In this paper, we studied a designed series of aldose reductase (AR) inhibitors. The series was derived from a known AR binder, which had previously been shown to form a halogen bond between its bromine atom and the oxygen atom of the Thr-113 side chain of AR. In the series, the strength of the halogen bond was modulated by two factors, namely bromine-iodine substitution and the fluorination of the aromatic ring in several positions. The role of the single halogen bond in AR-ligand binding was elucidated by advanced binding free energy calculations involving the semiempirical quantum chemical Hamiltonian. The results were complemented with ultrahigh-resolution X-ray crystallography and IC50 measurements. All of the AR inhibitors studied were shown by X-ray crystallography to bind in an identical manner. Further, it was demonstrated that it was possible to decrease the IC50 value by about 1 order of magnitude by tuning the strength of the halogen bond by a monoatomic substitution. The calculations revealed that the protein-ligand interaction energy increased upon the substitution of iodine for bromine or upon the addition of electron-withdrawing fluorine atoms to the ring. However, the effect on the binding affinity was found to be more complex due to the change of the solvation/desolvation properties within the ligand series. The study shows that it is possible to modulate the strength of a halogen bond in a protein-ligand complex as was designed based on the previous studies of low-molecular-weight complexes. | ||
- | + | Modulation of aldose reductase inhibition by halogen bond tuning.,Fanfrlik J, Kolar M, Kamlar M, Hurny D, Ruiz FX, Cousido-Siah A, Mitschler A, Rezac J, Munusamy E, Lepsik M, Matejicek P, Vesely J, Podjarny A, Hobza P ACS Chem Biol. 2013 Nov 15;8(11):2484-92. doi: 10.1021/cb400526n. Epub 2013 Sep, 17. PMID:23988122<ref>PMID:23988122</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | + | == References == | |
- | + | <references/> | |
+ | __TOC__ | ||
+ | </StructureSection> | ||
+ | [[Category: Aldehyde reductase]] | ||
+ | [[Category: Cousido-Siah, A.]] | ||
+ | [[Category: Fanfrlik, J.]] | ||
+ | [[Category: Hobza, P.]] | ||
+ | [[Category: Kolar, M.]] | ||
+ | [[Category: Mitschler, A.]] | ||
+ | [[Category: Podjarny, A.]] | ||
+ | [[Category: Ruiz, F X.]] | ||
+ | [[Category: Aldose reductase]] | ||
+ | [[Category: Cytosolic]] | ||
+ | [[Category: Diabetes]] | ||
+ | [[Category: Halogenated compound]] | ||
+ | [[Category: Oxidoreductase]] | ||
+ | [[Category: Tim barrel]] |
Revision as of 07:41, 30 April 2014
Crystal structure of human AR complexed with NADP+ and {5-chloro-2-[(4-iodobenzyl)carbamoyl]phenoxy}acetic acid
|